The CBR was 45.7% (95% CI, 33.7–58.1) in all evaluable patients who received 120 mg/day palazestrant (n = 70) and 58.6% (95% CI, 38.9–76.5) in patients with cancers with ESR1 mutations (n = 29). The gene discussed is ESR1; the disease is cancer.